Rampant C→U Hypermutation in the Genomes of SARS-CoV-2 and Other Coronaviruses: Causes and Consequences for Their Short- and Long-Term Evolutionary Trajectories

The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The findi...

Full description

Saved in:
Bibliographic Details
Published in:mSphere Vol. 5; no. 3
Main Author: Simmonds, P.
Format: Journal Article
Language:English
Published: United States American Society for Microbiology 24.06.2020
Subjects:
ISSN:2379-5042, 2379-5042
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The finding that a large proportion of sequence change in SARS-CoV-2 in the initial months of the pandemic comprised C→U mutations in a host APOBEC-like context provides evidence for a potent host-driven antiviral editing mechanism against coronaviruses more often associated with antiretroviral defense. In evolutionary terms, the contribution of biased, convergent, and context-dependent mutations to sequence change in SARS-CoV-2 is substantial, and these processes are not incorporated by standard models used in molecular epidemiology investigations. The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated an intensive analysis of its molecular epidemiology following its worldwide spread. To understand the early evolutionary events following its emergence, a data set of 985 complete SARS-CoV-2 sequences was assembled. Variants showed a mean of 5.5 to 9.5 nucleotide differences from each other, consistent with a midrange coronavirus substitution rate of 3 × 10 −4 substitutions/site/year. Almost one-half of sequence changes were C→U transitions, with an 8-fold base frequency normalized directional asymmetry between C→U and U→C substitutions. Elevated ratios were observed in other recently emerged coronaviruses (SARS-CoV, Middle East respiratory syndrome [MERS]-CoV), and decreasing ratios were observed in other human coronaviruses (HCoV-NL63, -OC43, -229E, and -HKU1) proportionate to their increasing divergence. C→U transitions underpinned almost one-half of the amino acid differences between SARS-CoV-2 variants and occurred preferentially in both 5′ U/A and 3′ U/A flanking sequence contexts comparable to favored motifs of human APOBEC3 proteins. Marked base asymmetries observed in nonpandemic human coronaviruses (U ≫ A > G ≫ C) and low G+C contents may represent long-term effects of prolonged C→U hypermutation in their hosts. The evidence that much of sequence change in SARS-CoV-2 and other coronaviruses may be driven by a host APOBEC-like editing process has profound implications for understanding their short- and long-term evolution. Repeated cycles of mutation and reversion in favored mutational hot spots and the widespread occurrence of amino acid changes with no adaptive value for the virus represent a quite different paradigm of virus sequence change from neutral and Darwinian evolutionary frameworks and are not incorporated by standard models used in molecular epidemiology investigations. IMPORTANCE The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The finding that a large proportion of sequence change in SARS-CoV-2 in the initial months of the pandemic comprised C→U mutations in a host APOBEC-like context provides evidence for a potent host-driven antiviral editing mechanism against coronaviruses more often associated with antiretroviral defense. In evolutionary terms, the contribution of biased, convergent, and context-dependent mutations to sequence change in SARS-CoV-2 is substantial, and these processes are not incorporated by standard models used in molecular epidemiology investigations.
AbstractList The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated an intensive analysis of its molecular epidemiology following its worldwide spread. To understand the early evolutionary events following its emergence, a data set of 985 complete SARS-CoV-2 sequences was assembled. Variants showed a mean of 5.5 to 9.5 nucleotide differences from each other, consistent with a midrange coronavirus substitution rate of 3 × 10 substitutions/site/year. Almost one-half of sequence changes were C→U transitions, with an 8-fold base frequency normalized directional asymmetry between C→U and U→C substitutions. Elevated ratios were observed in other recently emerged coronaviruses (SARS-CoV, Middle East respiratory syndrome [MERS]-CoV), and decreasing ratios were observed in other human coronaviruses (HCoV-NL63, -OC43, -229E, and -HKU1) proportionate to their increasing divergence. C→U transitions underpinned almost one-half of the amino acid differences between SARS-CoV-2 variants and occurred preferentially in both 5' U/A and 3' U/A flanking sequence contexts comparable to favored motifs of human APOBEC3 proteins. Marked base asymmetries observed in nonpandemic human coronaviruses (U ≫ A > G ≫ C) and low G+C contents may represent long-term effects of prolonged C→U hypermutation in their hosts. The evidence that much of sequence change in SARS-CoV-2 and other coronaviruses may be driven by a host APOBEC-like editing process has profound implications for understanding their short- and long-term evolution. Repeated cycles of mutation and reversion in favored mutational hot spots and the widespread occurrence of amino acid changes with no adaptive value for the virus represent a quite different paradigm of virus sequence change from neutral and Darwinian evolutionary frameworks and are not incorporated by standard models used in molecular epidemiology investigations. The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The finding that a large proportion of sequence change in SARS-CoV-2 in the initial months of the pandemic comprised C→U mutations in a host APOBEC-like context provides evidence for a potent host-driven antiviral editing mechanism against coronaviruses more often associated with antiretroviral defense. In evolutionary terms, the contribution of biased, convergent, and context-dependent mutations to sequence change in SARS-CoV-2 is substantial, and these processes are not incorporated by standard models used in molecular epidemiology investigations.
The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The finding that a large proportion of sequence change in SARS-CoV-2 in the initial months of the pandemic comprised C→U mutations in a host APOBEC-like context provides evidence for a potent host-driven antiviral editing mechanism against coronaviruses more often associated with antiretroviral defense. In evolutionary terms, the contribution of biased, convergent, and context-dependent mutations to sequence change in SARS-CoV-2 is substantial, and these processes are not incorporated by standard models used in molecular epidemiology investigations. The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated an intensive analysis of its molecular epidemiology following its worldwide spread. To understand the early evolutionary events following its emergence, a data set of 985 complete SARS-CoV-2 sequences was assembled. Variants showed a mean of 5.5 to 9.5 nucleotide differences from each other, consistent with a midrange coronavirus substitution rate of 3 × 10−4 substitutions/site/year. Almost one-half of sequence changes were C→U transitions, with an 8-fold base frequency normalized directional asymmetry between C→U and U→C substitutions. Elevated ratios were observed in other recently emerged coronaviruses (SARS-CoV, Middle East respiratory syndrome [MERS]-CoV), and decreasing ratios were observed in other human coronaviruses (HCoV-NL63, -OC43, -229E, and -HKU1) proportionate to their increasing divergence. C→U transitions underpinned almost one-half of the amino acid differences between SARS-CoV-2 variants and occurred preferentially in both 5′ U/A and 3′ U/A flanking sequence contexts comparable to favored motifs of human APOBEC3 proteins. Marked base asymmetries observed in nonpandemic human coronaviruses (U ≫ A > G ≫ C) and low G+C contents may represent long-term effects of prolonged C→U hypermutation in their hosts. The evidence that much of sequence change in SARS-CoV-2 and other coronaviruses may be driven by a host APOBEC-like editing process has profound implications for understanding their short- and long-term evolution. Repeated cycles of mutation and reversion in favored mutational hot spots and the widespread occurrence of amino acid changes with no adaptive value for the virus represent a quite different paradigm of virus sequence change from neutral and Darwinian evolutionary frameworks and are not incorporated by standard models used in molecular epidemiology investigations. IMPORTANCE The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The finding that a large proportion of sequence change in SARS-CoV-2 in the initial months of the pandemic comprised C→U mutations in a host APOBEC-like context provides evidence for a potent host-driven antiviral editing mechanism against coronaviruses more often associated with antiretroviral defense. In evolutionary terms, the contribution of biased, convergent, and context-dependent mutations to sequence change in SARS-CoV-2 is substantial, and these processes are not incorporated by standard models used in molecular epidemiology investigations.
ABSTRACTThe pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated an intensive analysis of its molecular epidemiology following its worldwide spread. To understand the early evolutionary events following its emergence, a data set of 985 complete SARS-CoV-2 sequences was assembled. Variants showed a mean of 5.5 to 9.5 nucleotide differences from each other, consistent with a midrange coronavirus substitution rate of 3 × 10−4 substitutions/site/year. Almost one-half of sequence changes were C→U transitions, with an 8-fold base frequency normalized directional asymmetry between C→U and U→C substitutions. Elevated ratios were observed in other recently emerged coronaviruses (SARS-CoV, Middle East respiratory syndrome [MERS]-CoV), and decreasing ratios were observed in other human coronaviruses (HCoV-NL63, -OC43, -229E, and -HKU1) proportionate to their increasing divergence. C→U transitions underpinned almost one-half of the amino acid differences between SARS-CoV-2 variants and occurred preferentially in both 5′ U/A and 3′ U/A flanking sequence contexts comparable to favored motifs of human APOBEC3 proteins. Marked base asymmetries observed in nonpandemic human coronaviruses (U ≫ A > G ≫ C) and low G+C contents may represent long-term effects of prolonged C→U hypermutation in their hosts. The evidence that much of sequence change in SARS-CoV-2 and other coronaviruses may be driven by a host APOBEC-like editing process has profound implications for understanding their short- and long-term evolution. Repeated cycles of mutation and reversion in favored mutational hot spots and the widespread occurrence of amino acid changes with no adaptive value for the virus represent a quite different paradigm of virus sequence change from neutral and Darwinian evolutionary frameworks and are not incorporated by standard models used in molecular epidemiology investigations.IMPORTANCE The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The finding that a large proportion of sequence change in SARS-CoV-2 in the initial months of the pandemic comprised C→U mutations in a host APOBEC-like context provides evidence for a potent host-driven antiviral editing mechanism against coronaviruses more often associated with antiretroviral defense. In evolutionary terms, the contribution of biased, convergent, and context-dependent mutations to sequence change in SARS-CoV-2 is substantial, and these processes are not incorporated by standard models used in molecular epidemiology investigations.
ABSTRACT The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated an intensive analysis of its molecular epidemiology following its worldwide spread. To understand the early evolutionary events following its emergence, a data set of 985 complete SARS-CoV-2 sequences was assembled. Variants showed a mean of 5.5 to 9.5 nucleotide differences from each other, consistent with a midrange coronavirus substitution rate of 3 × 10−4 substitutions/site/year. Almost one-half of sequence changes were C→U transitions, with an 8-fold base frequency normalized directional asymmetry between C→U and U→C substitutions. Elevated ratios were observed in other recently emerged coronaviruses (SARS-CoV, Middle East respiratory syndrome [MERS]-CoV), and decreasing ratios were observed in other human coronaviruses (HCoV-NL63, -OC43, -229E, and -HKU1) proportionate to their increasing divergence. C→U transitions underpinned almost one-half of the amino acid differences between SARS-CoV-2 variants and occurred preferentially in both 5′ U/A and 3′ U/A flanking sequence contexts comparable to favored motifs of human APOBEC3 proteins. Marked base asymmetries observed in nonpandemic human coronaviruses (U ≫ A > G ≫ C) and low G+C contents may represent long-term effects of prolonged C→U hypermutation in their hosts. The evidence that much of sequence change in SARS-CoV-2 and other coronaviruses may be driven by a host APOBEC-like editing process has profound implications for understanding their short- and long-term evolution. Repeated cycles of mutation and reversion in favored mutational hot spots and the widespread occurrence of amino acid changes with no adaptive value for the virus represent a quite different paradigm of virus sequence change from neutral and Darwinian evolutionary frameworks and are not incorporated by standard models used in molecular epidemiology investigations. IMPORTANCE The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The finding that a large proportion of sequence change in SARS-CoV-2 in the initial months of the pandemic comprised C→U mutations in a host APOBEC-like context provides evidence for a potent host-driven antiviral editing mechanism against coronaviruses more often associated with antiretroviral defense. In evolutionary terms, the contribution of biased, convergent, and context-dependent mutations to sequence change in SARS-CoV-2 is substantial, and these processes are not incorporated by standard models used in molecular epidemiology investigations.
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated an intensive analysis of its molecular epidemiology following its worldwide spread. To understand the early evolutionary events following its emergence, a data set of 985 complete SARS-CoV-2 sequences was assembled. Variants showed a mean of 5.5 to 9.5 nucleotide differences from each other, consistent with a midrange coronavirus substitution rate of 3 × 10-4 substitutions/site/year. Almost one-half of sequence changes were C→U transitions, with an 8-fold base frequency normalized directional asymmetry between C→U and U→C substitutions. Elevated ratios were observed in other recently emerged coronaviruses (SARS-CoV, Middle East respiratory syndrome [MERS]-CoV), and decreasing ratios were observed in other human coronaviruses (HCoV-NL63, -OC43, -229E, and -HKU1) proportionate to their increasing divergence. C→U transitions underpinned almost one-half of the amino acid differences between SARS-CoV-2 variants and occurred preferentially in both 5' U/A and 3' U/A flanking sequence contexts comparable to favored motifs of human APOBEC3 proteins. Marked base asymmetries observed in nonpandemic human coronaviruses (U ≫ A > G ≫ C) and low G+C contents may represent long-term effects of prolonged C→U hypermutation in their hosts. The evidence that much of sequence change in SARS-CoV-2 and other coronaviruses may be driven by a host APOBEC-like editing process has profound implications for understanding their short- and long-term evolution. Repeated cycles of mutation and reversion in favored mutational hot spots and the widespread occurrence of amino acid changes with no adaptive value for the virus represent a quite different paradigm of virus sequence change from neutral and Darwinian evolutionary frameworks and are not incorporated by standard models used in molecular epidemiology investigations.IMPORTANCE The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The finding that a large proportion of sequence change in SARS-CoV-2 in the initial months of the pandemic comprised C→U mutations in a host APOBEC-like context provides evidence for a potent host-driven antiviral editing mechanism against coronaviruses more often associated with antiretroviral defense. In evolutionary terms, the contribution of biased, convergent, and context-dependent mutations to sequence change in SARS-CoV-2 is substantial, and these processes are not incorporated by standard models used in molecular epidemiology investigations.The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated an intensive analysis of its molecular epidemiology following its worldwide spread. To understand the early evolutionary events following its emergence, a data set of 985 complete SARS-CoV-2 sequences was assembled. Variants showed a mean of 5.5 to 9.5 nucleotide differences from each other, consistent with a midrange coronavirus substitution rate of 3 × 10-4 substitutions/site/year. Almost one-half of sequence changes were C→U transitions, with an 8-fold base frequency normalized directional asymmetry between C→U and U→C substitutions. Elevated ratios were observed in other recently emerged coronaviruses (SARS-CoV, Middle East respiratory syndrome [MERS]-CoV), and decreasing ratios were observed in other human coronaviruses (HCoV-NL63, -OC43, -229E, and -HKU1) proportionate to their increasing divergence. C→U transitions underpinned almost one-half of the amino acid differences between SARS-CoV-2 variants and occurred preferentially in both 5' U/A and 3' U/A flanking sequence contexts comparable to favored motifs of human APOBEC3 proteins. Marked base asymmetries observed in nonpandemic human coronaviruses (U ≫ A > G ≫ C) and low G+C contents may represent long-term effects of prolonged C→U hypermutation in their hosts. The evidence that much of sequence change in SARS-CoV-2 and other coronaviruses may be driven by a host APOBEC-like editing process has profound implications for understanding their short- and long-term evolution. Repeated cycles of mutation and reversion in favored mutational hot spots and the widespread occurrence of amino acid changes with no adaptive value for the virus represent a quite different paradigm of virus sequence change from neutral and Darwinian evolutionary frameworks and are not incorporated by standard models used in molecular epidemiology investigations.IMPORTANCE The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The finding that a large proportion of sequence change in SARS-CoV-2 in the initial months of the pandemic comprised C→U mutations in a host APOBEC-like context provides evidence for a potent host-driven antiviral editing mechanism against coronaviruses more often associated with antiretroviral defense. In evolutionary terms, the contribution of biased, convergent, and context-dependent mutations to sequence change in SARS-CoV-2 is substantial, and these processes are not incorporated by standard models used in molecular epidemiology investigations.
The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The finding that a large proportion of sequence change in SARS-CoV-2 in the initial months of the pandemic comprised C→U mutations in a host APOBEC-like context provides evidence for a potent host-driven antiviral editing mechanism against coronaviruses more often associated with antiretroviral defense. In evolutionary terms, the contribution of biased, convergent, and context-dependent mutations to sequence change in SARS-CoV-2 is substantial, and these processes are not incorporated by standard models used in molecular epidemiology investigations. The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated an intensive analysis of its molecular epidemiology following its worldwide spread. To understand the early evolutionary events following its emergence, a data set of 985 complete SARS-CoV-2 sequences was assembled. Variants showed a mean of 5.5 to 9.5 nucleotide differences from each other, consistent with a midrange coronavirus substitution rate of 3 × 10 −4 substitutions/site/year. Almost one-half of sequence changes were C→U transitions, with an 8-fold base frequency normalized directional asymmetry between C→U and U→C substitutions. Elevated ratios were observed in other recently emerged coronaviruses (SARS-CoV, Middle East respiratory syndrome [MERS]-CoV), and decreasing ratios were observed in other human coronaviruses (HCoV-NL63, -OC43, -229E, and -HKU1) proportionate to their increasing divergence. C→U transitions underpinned almost one-half of the amino acid differences between SARS-CoV-2 variants and occurred preferentially in both 5′ U/A and 3′ U/A flanking sequence contexts comparable to favored motifs of human APOBEC3 proteins. Marked base asymmetries observed in nonpandemic human coronaviruses (U ≫ A > G ≫ C) and low G+C contents may represent long-term effects of prolonged C→U hypermutation in their hosts. The evidence that much of sequence change in SARS-CoV-2 and other coronaviruses may be driven by a host APOBEC-like editing process has profound implications for understanding their short- and long-term evolution. Repeated cycles of mutation and reversion in favored mutational hot spots and the widespread occurrence of amino acid changes with no adaptive value for the virus represent a quite different paradigm of virus sequence change from neutral and Darwinian evolutionary frameworks and are not incorporated by standard models used in molecular epidemiology investigations. IMPORTANCE The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate provides a relatively blank canvas with which to investigate effects of mutational and editing processes imposed by the host cell. The finding that a large proportion of sequence change in SARS-CoV-2 in the initial months of the pandemic comprised C→U mutations in a host APOBEC-like context provides evidence for a potent host-driven antiviral editing mechanism against coronaviruses more often associated with antiretroviral defense. In evolutionary terms, the contribution of biased, convergent, and context-dependent mutations to sequence change in SARS-CoV-2 is substantial, and these processes are not incorporated by standard models used in molecular epidemiology investigations.
Author Simmonds, P.
Author_xml – sequence: 1
  givenname: P.
  orcidid: 0000-0002-7964-4700
  surname: Simmonds
  fullname: Simmonds, P.
  organization: Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32581081$$D View this record in MEDLINE/PubMed
BookMark eNp1ks9q3DAQxk1JadI0956KoJdenOqPLVs9FIJJk8BCILvpVWjl8VqLLW0leyEv0AfoI_TR-iSVdzclCfQ0YubTNz-G721yZJ2FJHlP8DkhtPzczzcteDjHOMNlSvGr5ISyQqQ5zujRk_dxchbCGmNMOOW84G-SY0bzkuCSnCS_71S_UXZA1Z-fv-7R9cMGfD8OajDOImPR0AK6Aut6CMg1aH5xN08r9z2lSNka3caxR5Xzzqqt8WOA8AVVaqq7eeVsgB8jWB0bjfNo0YLxaN46P6Q7xczZVbqIO9Hl1nXjtFb5B7Twag16cN5AeJe8blQX4OxQT5P7b5eL6jqd3V7dVBezVGcCDyldAoZCU8ZYTXIKtW6yGgSorKghF0JoJThw3pQlKchS09gRGDNGKIFGYXaa3Ox9a6fWcuNNH0mkU0buGs6vpPKD0R1I4A3HtKCKU5HVTVEKyjURuaaUZaKpo9fXvddmXPYRBezgVffM9PnEmlau3FYWjPBM0Gjw6WDgXTxgGGRvgoauUxbcGCTNSMEEJuXE_fGFdO1Gb-Opoiry5aLMRFR9eEr0D-UxClHA9wLtXQgeGqnNPgcR0HSSYDnFTh5iJ3exk3Taj198fPT-75e_y9bd-w
CitedBy_id crossref_primary_10_1002_jobm_202000537
crossref_primary_10_1017_S095026882100220X
crossref_primary_10_1371_journal_ppat_1009596
crossref_primary_10_1093_abt_tbab015
crossref_primary_10_1186_s12985_023_01995_3
crossref_primary_10_7717_peerj_10181
crossref_primary_10_1016_j_jsps_2021_09_006
crossref_primary_10_1371_journal_ppat_1010068
crossref_primary_10_1093_ve_veaf047
crossref_primary_10_1002_advs_202205445
crossref_primary_10_1016_j_cell_2021_08_017
crossref_primary_10_3390_v15020321
crossref_primary_10_3390_v12101095
crossref_primary_10_7717_peerj_16962
crossref_primary_10_1002_rai2_12065
crossref_primary_10_1093_nar_gkaf261
crossref_primary_10_3390_ijms232314683
crossref_primary_10_1016_j_jcvp_2021_100037
crossref_primary_10_1016_j_clim_2021_108699
crossref_primary_10_1099_jgv_0_001584
crossref_primary_10_1186_s40246_023_00515_2
crossref_primary_10_3390_microorganisms8121976
crossref_primary_10_1016_j_coviro_2023_101326
crossref_primary_10_3390_v13061084
crossref_primary_10_1111_tbed_13931
crossref_primary_10_1128_spectrum_00221_22
crossref_primary_10_1093_molbev_msac156
crossref_primary_10_1128_msphere_00913_21
crossref_primary_10_3389_fmicb_2021_665041
crossref_primary_10_1371_journal_pgen_1009175
crossref_primary_10_1007_s13353_023_00756_w
crossref_primary_10_1038_s41576_021_00408_x
crossref_primary_10_1016_j_virol_2020_12_018
crossref_primary_10_3389_fmed_2022_1008600
crossref_primary_10_1261_rna_079160_122
crossref_primary_10_3389_fmed_2022_835998
crossref_primary_10_1016_j_genrep_2021_101045
crossref_primary_10_1093_nargab_lqae009
crossref_primary_10_1016_j_cmi_2021_02_024
crossref_primary_10_1128_jvi_02077_21
crossref_primary_10_1080_07391102_2023_2222832
crossref_primary_10_1186_s12985_021_01633_w
crossref_primary_10_1093_molbev_msaf059
crossref_primary_10_2478_acph_2025_0024
crossref_primary_10_1093_ve_veab020
crossref_primary_10_3390_v16101524
crossref_primary_10_1038_s41598_022_19067_x
crossref_primary_10_1128_mSphere_00219_21
crossref_primary_10_1099_mgen_0_000751
crossref_primary_10_3390_biology10010052
crossref_primary_10_1186_s13073_024_01409_1
crossref_primary_10_3389_fimmu_2021_690416
crossref_primary_10_1038_s41423_023_01104_y
crossref_primary_10_1093_bib_bbac513
crossref_primary_10_1093_ve_veab013
crossref_primary_10_1186_s12860_021_00403_4
crossref_primary_10_1093_oxfimm_iqac003
crossref_primary_10_1093_gigascience_giac079
crossref_primary_10_12688_f1000research_72896_3
crossref_primary_10_1111_febs_16230
crossref_primary_10_12688_f1000research_72896_4
crossref_primary_10_12688_f1000research_72896_1
crossref_primary_10_2217_fmb_2020_0300
crossref_primary_10_12688_f1000research_72896_2
crossref_primary_10_3390_microorganisms9050926
crossref_primary_10_1016_j_virusres_2022_198786
crossref_primary_10_1007_s13353_022_00698_9
crossref_primary_10_1186_s13073_021_00847_5
crossref_primary_10_3390_v13091800
crossref_primary_10_1371_journal_pone_0237689
crossref_primary_10_7554_eLife_66857
crossref_primary_10_1093_bib_bbab382
crossref_primary_10_1134_S0006297921030020
crossref_primary_10_3389_fvets_2021_644414
crossref_primary_10_1016_j_gpb_2020_10_003
crossref_primary_10_1016_j_heliyon_2024_e32139
crossref_primary_10_1093_ve_veae115
crossref_primary_10_3390_v15010167
crossref_primary_10_1093_nar_gkab1297
crossref_primary_10_1371_journal_pone_0273860
crossref_primary_10_1016_j_virusres_2020_198233
crossref_primary_10_1093_infdis_jiaf294
crossref_primary_10_1016_j_bbrc_2020_10_092
crossref_primary_10_15252_emmm_202114062
crossref_primary_10_1155_2022_5618222
crossref_primary_10_1038_s41576_022_00483_8
crossref_primary_10_1016_j_isci_2025_112873
crossref_primary_10_3390_cells10061557
crossref_primary_10_5662_wjm_v14_i3_89761
crossref_primary_10_1002_jmv_70353
crossref_primary_10_1093_ve_veab041
crossref_primary_10_1371_journal_pone_0247196
crossref_primary_10_3390_v14040796
crossref_primary_10_1016_j_tig_2021_07_003
crossref_primary_10_1128_mSphere_00019_21
crossref_primary_10_1038_s41525_025_00463_x
crossref_primary_10_1016_j_heliyon_2022_e09449
crossref_primary_10_1186_s13062_023_00366_w
crossref_primary_10_1038_s41586_021_04188_6
crossref_primary_10_3390_v13020290
crossref_primary_10_1016_j_cels_2021_09_013
crossref_primary_10_1038_s41467_020_19818_2
crossref_primary_10_1126_science_abe5901
crossref_primary_10_1038_s44318_024_00314_y
crossref_primary_10_3390_v13030394
crossref_primary_10_1016_j_virol_2022_01_011
crossref_primary_10_1093_nar_gkaf503
crossref_primary_10_1093_nar_gkac1238
crossref_primary_10_3389_fcimb_2024_1476605
crossref_primary_10_1016_j_jiac_2022_01_019
crossref_primary_10_1186_s12985_023_01982_8
crossref_primary_10_3390_genes12060826
crossref_primary_10_1186_s12864_022_08664_9
crossref_primary_10_1016_j_virol_2025_110607
crossref_primary_10_1002_jmv_29128
crossref_primary_10_1186_s13059_023_02881_5
crossref_primary_10_7759_cureus_33316
crossref_primary_10_1016_j_isci_2023_108031
crossref_primary_10_1126_science_abp8337
crossref_primary_10_1007_s00239_021_10008_2
crossref_primary_10_1093_molbev_msac028
crossref_primary_10_1016_j_banm_2021_11_002
crossref_primary_10_1016_j_micpath_2024_106796
crossref_primary_10_3390_pathogens9110912
crossref_primary_10_1371_journal_pbio_3001115
crossref_primary_10_1093_molbev_msaa247
crossref_primary_10_1093_molbev_msac029
crossref_primary_10_1093_emph_eoab019
crossref_primary_10_12998_wjcc_v9_i1_1
crossref_primary_10_1371_journal_pone_0255169
crossref_primary_10_3390_life11080734
crossref_primary_10_1038_s12276_021_00658_z
crossref_primary_10_1093_nar_gkaf447
crossref_primary_10_3390_pathogens11060662
crossref_primary_10_1016_j_gene_2022_147020
crossref_primary_10_1016_j_jinf_2024_106150
crossref_primary_10_1186_s12879_025_11355_x
crossref_primary_10_3390_ijms24109072
crossref_primary_10_3390_v16071141
crossref_primary_10_1038_s41579_023_00878_2
crossref_primary_10_1111_1462_2920_15487
crossref_primary_10_1002_wrna_1679
crossref_primary_10_1371_journal_pcbi_1011795
crossref_primary_10_12688_f1000research_52540_3
crossref_primary_10_12688_f1000research_52540_2
crossref_primary_10_3390_v15051152
crossref_primary_10_12688_f1000research_52540_1
crossref_primary_10_1016_j_virol_2024_110366
crossref_primary_10_1016_j_virusres_2022_198753
Cites_doi 10.1038/nature01707
10.1016/j.virol.2015.03.012
10.1186/1471-2148-12-71
10.1371/journal.pbio.0020275
10.1056/NEJMoa2001017
10.1038/srep39100
10.1126/sciadv.abb5813
10.1186/1756-0500-5-50
10.1016/j.antiviral.2019.03.005
10.1038/nature01709
10.1038/s41586-020-2012-7
10.1186/s13059-019-1651-1
10.1016/0042-6822(92)91195-z
10.1186/s13059-019-1659-6
10.1128/JVI.01296-07
10.1038/ncomms7881
10.1126/science.1100658
10.1038/s41586-020-2008-3
10.1016/j.meegid.2018.04.031
10.1016/j.virusres.2014.11.031
10.1073/pnas.91.8.3092
10.1016/j.virol.2010.12.004
10.1016/j.prevetmed.2015.11.001
10.1186/1471-2164-14-610
10.1099/vir.0.038919-0
10.1056/NEJMoa2001316
10.1093/molbev/mst197
10.1128/jvi.78.3.1602-1603.2004
10.1038/s41598-018-24448-2
10.1093/nar/gkz1164
10.1128/mBio.01062-13
10.1016/j.virol.2007.08.010
10.1111/j.1863-2378.2012.01528.x
10.1371/journal.ppat.1003565
10.1371/journal.pone.0030036
10.1128/JVI.79.5.3223-3225.2005
10.1016/s0092-8674(03)00423-9
10.1016/bs.aivir.2018.01.001
10.1074/jbc.M602367200
10.1371/journal.ppat.1000896
ContentType Journal Article
Copyright Copyright © 2020 Simmonds.
Copyright © 2020 Simmonds. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright © 2020 Simmonds. 2020 Simmonds
Copyright_xml – notice: Copyright © 2020 Simmonds.
– notice: Copyright © 2020 Simmonds. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright © 2020 Simmonds. 2020 Simmonds
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1128/mSphere.00408-20
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

Publicly Available Content Database

MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate C→U Hypermutation in SARS Coronavirus 2
EISSN 2379-5042
ExternalDocumentID oai_doaj_org_article_e6f60272a6294df78926c195c22349fd
PMC7316492
32581081
10_1128_mSphere_00408_20
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Wellcome Trust
  grantid: WT103767MA
– fundername: Wellcome Trust
– fundername: ;
  grantid: WT103767MA
GroupedDBID 0R~
53G
5VS
7X7
8FE
8FH
8FI
8FJ
AAFWJ
AAGFI
AAUOK
AAYXX
ABUWG
ADBBV
AFFHD
AFKRA
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
DIK
EBS
FRP
FYUFA
GROUPED_DOAJ
H13
HCIFZ
HMCUK
HYE
KQ8
LK8
M48
M7P
M~E
O9-
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PQQKQ
PROAC
R9-
RHI
RPM
RSF
UKHRP
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
COVID
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c490t-2be0e7c2333d152edcf4de9ea47de5999ca96e66f88171bc299c90033121efa03
IEDL.DBID DOA
ISICitedReferencesCount 147
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000569211400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2379-5042
IngestDate Fri Oct 03 12:50:32 EDT 2025
Tue Nov 04 01:57:24 EST 2025
Thu Oct 02 11:05:28 EDT 2025
Tue Oct 07 06:58:49 EDT 2025
Thu Apr 03 07:05:44 EDT 2025
Sat Nov 29 03:33:44 EST 2025
Tue Nov 18 22:11:25 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords COVID-19
SARS-CoV-2
APOBEC
SARS
coronavirus
SARS coronavirus 2
hypermutation
Language English
License Copyright © 2020 Simmonds.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c490t-2be0e7c2333d152edcf4de9ea47de5999ca96e66f88171bc299c90033121efa03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Citation Simmonds P. 2020. Rampant C→U hypermutation in the genomes of SARS-CoV-2 and other coronaviruses: causes and consequences for their short- and long-term evolutionary trajectories. mSphere 5:e00408-20. https://doi.org/10.1128/mSphere.00408-20.
ORCID 0000-0002-7964-4700
OpenAccessLink https://doaj.org/article/e6f60272a6294df78926c195c22349fd
PMID 32581081
PQID 2429459849
PQPubID 2045592
ParticipantIDs doaj_primary_oai_doaj_org_article_e6f60272a6294df78926c195c22349fd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7316492
proquest_miscellaneous_2417390180
proquest_journals_2429459849
pubmed_primary_32581081
crossref_citationtrail_10_1128_mSphere_00408_20
crossref_primary_10_1128_mSphere_00408_20
PublicationCentury 2000
PublicationDate 20200624
PublicationDateYYYYMMDD 2020-06-24
PublicationDate_xml – month: 6
  year: 2020
  text: 20200624
  day: 24
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
– name: 1752 N St., N.W., Washington, DC
PublicationTitle mSphere
PublicationTitleAlternate mSphere
PublicationYear 2020
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_41_2
e_1_3_2_40_2
e_1_3_2_20_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_22_2
e_1_3_2_23_2
e_1_3_2_24_2
e_1_3_2_25_2
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
e_1_3_2_14_2
e_1_3_2_35_2
Mavian C (e_1_3_2_6_2) 2020
References_xml – ident: e_1_3_2_20_2
  doi: 10.1038/nature01707
– ident: e_1_3_2_24_2
  doi: 10.1016/j.virol.2015.03.012
– ident: e_1_3_2_25_2
  doi: 10.1186/1471-2148-12-71
– ident: e_1_3_2_27_2
  doi: 10.1371/journal.pbio.0020275
– ident: e_1_3_2_4_2
  doi: 10.1056/NEJMoa2001017
– ident: e_1_3_2_35_2
  doi: 10.1038/srep39100
– ident: e_1_3_2_37_2
  doi: 10.1126/sciadv.abb5813
– ident: e_1_3_2_41_2
  doi: 10.1186/1756-0500-5-50
– ident: e_1_3_2_31_2
  doi: 10.1016/j.antiviral.2019.03.005
– ident: e_1_3_2_21_2
  doi: 10.1038/nature01709
– ident: e_1_3_2_3_2
  doi: 10.1038/s41586-020-2012-7
– ident: e_1_3_2_34_2
  doi: 10.1186/s13059-019-1651-1
– ident: e_1_3_2_11_2
  doi: 10.1016/0042-6822(92)91195-z
– ident: e_1_3_2_18_2
  doi: 10.1186/s13059-019-1659-6
– ident: e_1_3_2_9_2
  doi: 10.1128/JVI.01296-07
– ident: e_1_3_2_33_2
  doi: 10.1038/ncomms7881
– ident: e_1_3_2_29_2
  doi: 10.1126/science.1100658
– ident: e_1_3_2_5_2
  doi: 10.1038/s41586-020-2008-3
– ident: e_1_3_2_13_2
  doi: 10.1016/j.meegid.2018.04.031
– ident: e_1_3_2_38_2
  doi: 10.1016/j.virusres.2014.11.031
– ident: e_1_3_2_23_2
  doi: 10.1073/pnas.91.8.3092
– ident: e_1_3_2_19_2
  doi: 10.1016/j.virol.2010.12.004
– ident: e_1_3_2_14_2
  doi: 10.1016/j.prevetmed.2015.11.001
– ident: e_1_3_2_17_2
  doi: 10.1186/1471-2164-14-610
– ident: e_1_3_2_30_2
  doi: 10.1099/vir.0.038919-0
– ident: e_1_3_2_2_2
  doi: 10.1056/NEJMoa2001316
– ident: e_1_3_2_42_2
  doi: 10.1093/molbev/mst197
– ident: e_1_3_2_10_2
  doi: 10.1128/jvi.78.3.1602-1603.2004
– ident: e_1_3_2_32_2
  doi: 10.1038/s41598-018-24448-2
– ident: e_1_3_2_36_2
  doi: 10.1093/nar/gkz1164
– ident: e_1_3_2_15_2
  doi: 10.1128/mBio.01062-13
– ident: e_1_3_2_16_2
  doi: 10.1016/j.virol.2007.08.010
– ident: e_1_3_2_39_2
  doi: 10.1111/j.1863-2378.2012.01528.x
– year: 2020
  ident: e_1_3_2_6_2
  article-title: Regaining perspective on SARS-CoV-2 molecular tracing and its implications
  publication-title: medRxiv
– ident: e_1_3_2_7_2
  doi: 10.1371/journal.ppat.1003565
– ident: e_1_3_2_26_2
  doi: 10.1371/journal.pone.0030036
– ident: e_1_3_2_12_2
  doi: 10.1128/JVI.79.5.3223-3225.2005
– ident: e_1_3_2_22_2
  doi: 10.1016/s0092-8674(03)00423-9
– ident: e_1_3_2_40_2
  doi: 10.1016/bs.aivir.2018.01.001
– ident: e_1_3_2_28_2
  doi: 10.1074/jbc.M602367200
– ident: e_1_3_2_8_2
  doi: 10.1371/journal.ppat.1000896
SSID ssj0001626676
Score 2.5390484
Snippet The wealth of accurately curated sequence data for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its long genome, and its low substitution rate...
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated an intensive analysis of its molecular epidemiology following its...
ABSTRACTThe pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated an intensive analysis of its molecular epidemiology...
ABSTRACT The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated an intensive analysis of its molecular epidemiology...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
SubjectTerms Amino acid sequence
Antiretroviral drugs
Antiviral drugs
APOBEC
APOBEC Deaminases
Asymmetry
Base Composition - genetics
Base Sequence - genetics
Betacoronavirus - genetics
Coronaviridae
coronavirus
Coronavirus Infections - pathology
Coronaviruses
COVID-19
Cytidine Deaminase - genetics
Cytosine - analysis
Datasets
Disease transmission
Divergence
Ecological and Evolutionary Science
Epidemics
Epidemiology
Evolution
Genome, Viral - genetics
Genomes
Humans
hypermutation
Long-term effects
Mathematical models
Middle East Respiratory Syndrome Coronavirus - genetics
Molecular modelling
Mutation
Pandemics
Pneumonia, Viral - pathology
Polymorphism, Single Nucleotide - genetics
Reversion
RNA polymerase
SARS
SARS coronavirus 2
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Severe acute respiratory syndrome-related coronavirus - genetics
Uracil - analysis
Zoonoses
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NjtMwELagCxIX_n8CCzISFw6mjuPENhe0G3XZAyqrtov2FiWOvVtEkyVpK-0L8AA8Ao_Gk-BJ3e4Wob1wihRPlFH82fPNjDOD0JvQWlvQ0pDSCk64jiOiioiSQkgtEhWy0JRdswkxHMqTE3XkA26tP1a53hO7jbqsNcTI-86UKB4rydWH8-8EukZBdtW30LiJdqBSGe-hnf3B8Gh0GWVxfD0Rm_wkk_3ZGH7XN-8AvYCRLXvUle3_F9f8-8jkFRt0cO9_tb-P7nr2ifdWcHmAbpjqIbq96kd58Qj9GkH5xWqO098_fh7jQ-ejNrPFKlmPpxV2ZBF_NFU9My2uLR7vjcYkrb8QhvOqxJ-BS-IUSiLky2mzaE37Hqc5XLvx9MrBbey4Mp5AkgKPz5wHQDqJT3V1SibunXiw9Esiby6ws6dfu-SC8-ofo-ODwSQ9JL6JA9Fc0TlhhaFGaBZFUem4gvuClpdGmZyL0sSOnupcJSZJrJShCAvtzKOG6GoEMLE5jZ6gXlVX5hnCVFNTCmmUM6lc5nHhXCdNqY5lbkUh4wD111OZaV_hHBptfMs6T4fJzE9-1k1-xmiA3m6eOF9V97hGdh_QsZGDutzdjbo5zfwyz0xiE-foszxx8-3gLxVLdKhi7VgYV7YM0O4aH5nfLNrsEhwBer0Zdssccjd5ZeoFyIQCwlPS6fF0BcWNJhGLZeioXYDEFki3VN0eqaZnXSlx6FvGFXt-vVov0B0GYQaaEMZ3UW_eLMxLdEsv59O2eeXX3B_9wjs6
  priority: 102
  providerName: ProQuest
Title Rampant C→U Hypermutation in the Genomes of SARS-CoV-2 and Other Coronaviruses: Causes and Consequences for Their Short- and Long-Term Evolutionary Trajectories
URI https://www.ncbi.nlm.nih.gov/pubmed/32581081
https://www.proquest.com/docview/2429459849
https://www.proquest.com/docview/2417390180
https://pubmed.ncbi.nlm.nih.gov/PMC7316492
https://doaj.org/article/e6f60272a6294df78926c195c22349fd
Volume 5
WOSCitedRecordID wos000569211400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2379-5042
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001626676
  issn: 2379-5042
  databaseCode: DOA
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2379-5042
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001626676
  issn: 2379-5042
  databaseCode: M~E
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2379-5042
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001626676
  issn: 2379-5042
  databaseCode: M7P
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2379-5042
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001626676
  issn: 2379-5042
  databaseCode: 7X7
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2379-5042
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001626676
  issn: 2379-5042
  databaseCode: BENPR
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2379-5042
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001626676
  issn: 2379-5042
  databaseCode: PIMPY
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELZgAYkL4p_CUhmJCwdTx3Fim9tu1GWRoFRtF5VT5Dg2W0QT1D9pX4AH4BF4NJ6EsZOtWoTgwiWRbCdxPJ8z33icGYSeR865gpaWlE5wwk0SE1XElBRCGpGqiEW2DMkmxGAgp1M13En15feENeGBm4Hr2dSlYDoxnTLF4YZSsdREKjGg17hypf_6AuvZMabC6grw9FRs_ZJM9uZj_5u-felR67Gxp4dCuP4_cczft0ru6J6T2-hWSxrxUdPZO-iKre6iG00ayYt76MfIR02sVjj7-e37GT4F03IxXzc-djyrMHA8_NpW9dwuce3w-Gg0Jln9gTCsqxK_9xQQZz6Sgd7MFuulXb7CmfbnUJ_t7LfGQHHxxPsW8PgciDsJLd7W1ScygWfi_qZFsl5cYFCDn4NPAIzx--jspD_JTkmbe4EYruiKsMJSKwyL47gEFQ8D4HhpldVclDYBVmm0Sm2aOikjERUGtJrxi6Kxl67TNH6ADqq6so8QpobaUkirQBNyqZMCLB5DqUmkdqKQSQf1LiWRmzYwuc-P8SUPBgqTeSu7PMguZ7SDXmyv-NoE5fhL22Mv3G07H047FADI8hZk-b9A1kGHl9DI2zm-zIHcKJ4oyVUHPdtWw-z0Lhdd2Xrt20TCrypJ6MfDBknbnsQskREwsg4Sexjb6-p-TTU7DxHAfboxrtjj__FuT9BN5tcQaEoYP0QHq8XaPkXXzWY1Wy666KqYinCUXXTtuD8YjrphqnX9LtkhlA3fvBt-_AUShjDW
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3dbtMwFLbGAMEN_z-FAUaCCy5MHefHNhJCI2x0Wilo7VDvQuI4WxFNRtIW9QV4AB6BB-CheBJ8nLRbEdrdLriqVDvtUfKd4-_85ByEnjhZliU01STNuEc85btEJi4lCReKB9Jhjk7tsAne64nhUH5YQ78W78JAWeXCJlpDnRYKYuRtc5RIz5fCk6-OvhKYGgXZ1cUIjRoWu3r-zbhs1cudN-b5PmVse2sQdkgzVYAoT9IJYYmmmivmum5qDi-dqsxLtdSxx1PtG76kYhnoIMiEcLiTKGOvFYT7XJA7i6lrfvccOm_E4VBCxof8OKZjvIOAL7OhTLTHfWgOoJ-DrgAiV04_OyTgX8z27wLNEyfe9tX_7V5dQ1cabo03a2W4jtZ0fgNdrKdtzm-in3vQXDKf4PD39x_7uGM88HI8rUsR8CjHhgrjtzovxrrCRYb7m3t9EhYfCcNxnuL3wJRxCA0f4tmonFa6eoHDGD7teniiLB0bTwAPIAWD-4fGvyF2R7fID8jA_CfemjUKH5dzbNjCZ5s6GenqFto_kxt0G63nRa7vIkwV1SkXWhrC4InYT4xjqChVvogzngi_hdoL6ESq6d8OY0S-RNaPYyJqwBZZsEWMttCz5RVHde-SU_a-BjQu90HXcftFUR5EjRGLdJAFlHEWBwZfRrmFZIFypK8Mx_RklrbQxgKPUWMKq-gYjC30eLlsjBhkpuJcF1PY43AIvgkjx50a-ktJXOYLxxDXFuIrSrEi6upKPjq0jdJhKpsn2b3TxXqELnUG77pRd6e3ex9dZhBQoQFh3gZan5RT_QBdULPJqCofWm3H6NNZq8wf-SmXKw
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3dbtMwFLbGBogb_n8KA4wEF1yYOs6PbSSEtq5l06ZSrd20u5A49lZEk5G0RX0BHoBH4DF4HJ6E4yTtVoR2twuuKsVO6iTnO_7OT85B6KVjjIlpokliuEc85btExi4lMReKB9Jhjk7KZhO82xVHR7K3gn7Nv4WxaZVznVgq6iRT1kfehK1Eer4UnmyaOi2it9V5f_qV2A5SNtI6b6dRiciunn0D8614t7MF7_oVY532oLVN6g4DRHmSjgmLNdVcMdd1E9jIdKKMl2ipI48n2gfupCIZ6CAwQjjciRXobmVdf669BxNRF657Ba1xIBmArrXNdre3f-bhAVsh4IvYKBPNUd-WCtBvLHKsfC7thWXLgH_x3L_TNc_tf51b__OTu41u1qwbb1QwuYNWdHoXXav6cM7uoZ_7tuxkOsat399_HOBtsM3z0aRKUsDDFANJxh90mo10gTOD-xv7fdLKDgnDUZrgj5ZD45YtBRFNh_mk0MVb3IrsbzneOpewjsFGwAMbnMH9E7B8SDljL0uPyQD-E7entSqI8hkGHvG5DKoMdXEfHVzKA3qAVtMs1Y8QporqhAstgUp4IvJjMBkVpcoXkeGx8BuoORejUNWV3W2DkS9haeExEdaCF5aCFzLaQK8XZ5xWVU0umLtpJXMxz9YjLw9k-XFYq7dQByagjLMoAFkD2AsAhHKkr4B9etIkDbQ-l82wVpJFeCaYDfRiMQzqzcasolRnEzvH4dYtJ2AdDysYLFbiMl84QGkbiC8BZGmpyyPp8KQsoW77tXmSPb54Wc_RdUBKuLfT3X2CbjDraaEBYd46Wh3nE_0UXVXT8bDIn9XQx-jTZWPmD15HoUw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rampant+C%E2%86%92U+Hypermutation+in+the+Genomes+of+SARS-CoV-2+and+Other+Coronaviruses%3A+Causes+and+Consequences+for+Their+Short-+and+Long-Term+Evolutionary+Trajectories&rft.jtitle=mSphere&rft.au=Simmonds%2C+P&rft.date=2020-06-24&rft.eissn=2379-5042&rft.volume=5&rft.issue=3&rft_id=info:doi/10.1128%2FmSphere.00408-20&rft_id=info%3Apmid%2F32581081&rft.externalDocID=32581081
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2379-5042&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2379-5042&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2379-5042&client=summon